Document Detail


Vascular access and contrast media.
MedLine Citation:
PMID:  21399455     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Over the past several years, the Food and Drug Administration (FDA) has received more than 250 adverse event reports in which vascular access devices have ruptured when used with power injectors. The adverse events include rupture and device fragmentation. The outcome of these events affects both the patient and the care provider.
Authors:
Ann Earhart; Paula McMahon
Related Documents :
19382575 - Tempo tvc for the enumeration of aerobic mesophilic flora in foods: collaborative study.
17078755 - Evaluation of a model for escherichia coli o157:h7 colonization in streptomycin-treated...
3555755 - Icmsf methods study. xvii. an international comparative study of the direct plate and h...
15249065 - Influence of environmental cues on transcriptional regulation of foo and clp coding for...
23044855 - Sleeve gastrectomy and roux-en-y gastric bypass exhibit differential effects on food pr...
20730515 - Oral food desensitization.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of infusion nursing : the official publication of the Infusion Nurses Society     Volume:  34     ISSN:  1539-0667     ISO Abbreviation:  J Infus Nurs     Publication Date:    2011 Mar-Apr
Date Detail:
Created Date:  2011-03-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101124170     Medline TA:  J Infus Nurs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  97-105     Citation Subset:  N    
Affiliation:
Banner Health, Banner Good Samaritan Medical Center, Phoenix, Arizona.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The Effects of Needleless Connectors on Catheter-Related Thrombotic Occlusions.
Next Document:  New therapeutic options in rheumatoid arthritis: a focus on interleukin-6 blockade.